Hopfner F, Höglinger GU, Kuhlenbäumer G, et al. β-adrenoreceptors and the risk of Parkinson's disease. Lancet Neurol 2020; 19: 247–54—In this Rapid Review the sentence from the summary originally stated “β-adrenoceptor antagonists are used by billions of patients with neurological disorders, primarily for the treatment of migraine and action tremor (mainly essential tremor), worldwide.” This has been rewritten and is now “According to current treatment guidelines, more than a billion patients with neurological disorders have an indication for the use of β-adrenoceptor antagonists (mainly migraine and essential tremor)”. This correction has been made to the online version as of March 18, 2020.

中文翻译：

---

柳叶刀神经2020修正案; 19：247-54。

Hopfner F，HöglingerGU，KuhlenbäumerG等。β-肾上腺素受体和帕金森氏病的风险。柳叶刀神经科学2020; 19：247-54 —在此快速评论中，摘要中的句子最初指出：“全球数十亿神经系统疾病患者使用β-肾上腺素受体拮抗剂，主要用于治疗偏头痛和动作性震颤（主要是基本震颤）。” 这已被重写，现在是“根据当前的治疗指南，超过十亿的神经系统疾病患者有使用β-肾上腺素受体拮抗剂（主要是偏头痛和原发性震颤）的指征”。自2020年3月18日起对在线版本进行了更正。